Suppr超能文献

循证利尿疗法改善系统性高血压的心血管预后。

Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension.

机构信息

Mid America Heart and Vascular Institute, Saint Luke's Hospital and University of Missouri-Kansas City, Kansas City, Missouri, USA.

出版信息

Am J Cardiol. 2011 Apr 15;107(8):1178-84. doi: 10.1016/j.amjcard.2010.12.016.

Abstract

Diuretics are among the most commonly prescribed cardiovascular (CV) medications. The strength of evidence supporting the effectiveness of diuretics in lowering blood pressure and for preventing major adverse CV events in patients with hypertension varies considerably among diuretic classes and even among agents within the same class. Unfortunately, common prescribing habits among American physicians, including specialists in CV diseases, are not in line with the existing evidence regarding diuretic therapy for improving CV prognosis. In conclusion, although hydrochlorothiazide is the standard diuretic used for hypertension, the outcomes data suggest that chlorthalidone, indapamide, and possibly even the aldosterone receptor blockers (spironolactone and eplerenone) may be superior agents.

摘要

利尿剂是最常用的心血管 (CV) 药物之一。利尿剂在降低血压和预防高血压患者主要不良 CV 事件方面的有效性的证据强度在不同的利尿剂类别之间甚至在同一类别中的不同药物之间有很大差异。不幸的是,美国医生的常见处方习惯,包括心血管疾病专家,与利尿剂治疗改善 CV 预后的现有证据不符。总之,尽管氢氯噻嗪是用于治疗高血压的标准利尿剂,但结果数据表明,氯噻酮、吲达帕胺,甚至可能还有醛固酮受体阻滞剂(螺内酯和依普利酮)可能是更好的药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验